SCNI vs VNO · P/E 0.2, rev $1.3M vs rev $921.3M
Scinai Immunotherapeutics Ltd (SCNI) versus VNO (VNO) — a side-by-side from cached financials, not a winner call.
Scinai Immunotherapeutics Ltd (SCNI) is a biotechnology company listed on NASDAQ.
VNO (VNO) common stock.
Latest reported SCNI revenue for 2025-12-31 was $1.3M. Net income was -$8.3M. Revenue was up 99.2% from 2024-12-31 to 2025-12-31. SCNI currently screens at market cap $1.8M and trailing P/E 0.2.
Latest reported VNO revenue for 2026-06-30 was $921.3M. Net income was $24.6M. VNO currently screens at market cap $0.
SCNI currently screens at market cap $1.8M and trailing P/E 0.2. VNO currently screens at market cap $0.
Not investment advice. Open the SCNI and VNO stock pages for the full models.
Not investment advice.